DAO and schizophrenia: More specifically, as NMDAR hypofunction is a core pathway deficit in schizophrenia [19,20], DAAO inhibitors, perhaps in combination with D-serine systemic administration [21], have the potential to be effective treatments of schizophrenia via their capacity to increase D-serine in the brain and enhance NMDAR-dependent functions [13,14,22].